Current - Members - Nanomedicine Research Group

Login Form

Principal Investigator



Pieter Cullis, PhD, FRSC

Read More

 

Research Associates



Genc Basha, MD, PhD

The focus of my research includes the mechanism of uptake and intracellular trafficking of liposomal nanoparticles and gene targeting in antigen presenting cells (DCs) and tumor cells.


Ismail Hafez, PhD (Researchgate Profile)
2008 Human Frontiers Science Program Young Investigator

I have almost two decades of experience in the invention, creation, design, construction and characterization of liposomes and lipid nanoparticles for use in drug delivery. I have designed the first tunable pH-sensitive liposome system, and elucidated the mechanism of action of cationic lipids. My current work leverages my experience for understanding the mechanism of action of lipid nanoparticles currently in the clinic and developing novel delivery technologies.


Igor Zhigaltsev, PhD

My areas of interest include the design, formulation, physicochemical characterization and in vitro and in vivo evaluation of liposome-based drug forms. Specific methods and techniques used in my research include: preformed vesicle approach, remote loading techniques, freeze-fracture and transmission electron microscopy, evaluation of in vivo pharmacokinetics of liposomal drugs.

 

Post-doctoral Fellows



Roy van der Meel, PhD

The aim of my research is to develop a nanomedicine-based combination treatment and exosome-based companion diagnostic test for advanced prostate cancer. This project is in collaboration with the Vancouver Prostate Centre and the University Medical Center Utrecht in The Netherlands. The research is funded by a Marie Sklodowska-Curie grant from the European Union and a VENI Fellowship from the Netherlands Organisation for Scientific Research (NWO).

 

Graduate Students



Nisha Chander, B.Tech, M.Sc

Pending details.


Andrew Cottle, B.Sc

Pending details.


Jay Kulkarni, B.Sc

Pending details.


Mina Ordobadi, B.Sc

My project focuses on developing lipid nanoparticles for targeted delivery to bones. These nanoparticles can be loaded with a variety of small molecules and drugs using different encapsulation techniques and are potential therapeutics for treatment of bone diseases such as osteoporosis.


Joslyn Quick, B.Sc

My project continues the development of a therapeutic to treat advanced prostate cancer patients. This is accomplished through knockdown of the androgen receptor (AR) with AR small-interfering RNA (siRNA) encapsulated in lipid nanoparticles (LNP AR-siRNA). Current LNP AR-siRNA involve the integration of an exogenous targeting ligand, to specifically bind and target prostate cancer cells. The project is in collaboration with Dr. Paul S. Rennie (The Prostate Centre @ Vancouver General Hospital).

 

Technicians



Yan Liu, B.Sc

Pending details.


Cayetana Schluter, MSc
Laboratory Manager

Pending details.

 

Visiting Scientists and Associated Members



Theresa M. Allen, PhD, FRSC
Adjunct Professor, NanoMedicines Research Group, Dept. of Biochemistry & Molecular Biology, UBC, Vancouver
Professor Emeritus, Pharmacology & Oncology, University of Alberta, Edmonton
Co-founder and Strategic Advisor, Centre for Drug Research and Development (CDRD), Vancouver

 



Robert (Rob) Fraser, PhD
Co-Founder & Operations Officer BCPMI (BC Personalized Medicine Initiative)
Rob has been involved in pharmaceutical research and development community for over 13 years; group leader in Target Identification for Sanofi; Senior Director of Biology for Xenon Pharmaceuticals, Senior Director of Pharmacology and Site Director at Neuromed (now Zalicus) Director Project Evaluation, CDRD. With a strong background and success rate in the development of targeted therapeutics, and recognizing the need to better target the therapy to the individual to improve safety and efficacy, Dr. Fraser joined Dr. Cullis at the start of 2011 to establish the Personalized Medicine Initiative for BC, which is a major opportunity for multiple institutions and stakeholders within BC to work together to lead a transformative process that will improve healthcare in BC.

 

Copyright